BACKGROUND: In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR). The clinical significance of this reaction remains unknown. METHODS: Forty-five patients with CLL who were treated with lenalidomide in a phase 2 clinical trial were evaluated for the clinical features, intensity, and duration of TFR. Correlation was made with tumor response and the immune cellular microenvironment. Steroids for the prophylaxis of TFR was not given to patients in Group A (n = 29) whereas patients in Group B (n = 16) received low-dose prednisone as well as a slow dose escalation of lenalidomide for the prevention of TFR. RESULTS: Thirty (67%) patients experienced a TFR, with a grade 2 or 3 reaction (according to National Cancer Institute Common Toxicity Criteria [version 3.0]) observed in 33% of patients (47% in Group A and 9% in Group B; P = .05). The median time to onset of the TFR was 6 days, and was longer in the patients receiving prophylaxis (4 days vs 9 days, respectively; P = .01). A complete response was observed in 7 of 30 (23%) patients with TFR and 1 of 15 (7%) patients without TFR. The median progression-free survival was 19.9 months and 19.4 months, respectively, for patients with versus those without TFR (P = .92). CONCLUSIONS: TFR is a unique immune-mediated phenomenon noted with lenalidomide treatment only in patients with CLL that correlates with clinical response. It can be effectively managed with anti-inflammatory agents. 2010 American Cancer Society.
BACKGROUND: In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR). The clinical significance of this reaction remains unknown. METHODS: Forty-five patients with CLL who were treated with lenalidomide in a phase 2 clinical trial were evaluated for the clinical features, intensity, and duration of TFR. Correlation was made with tumor response and the immune cellular microenvironment. Steroids for the prophylaxis of TFR was not given to patients in Group A (n = 29) whereas patients in Group B (n = 16) received low-dose prednisone as well as a slow dose escalation of lenalidomide for the prevention of TFR. RESULTS: Thirty (67%) patients experienced a TFR, with a grade 2 or 3 reaction (according to National Cancer Institute Common Toxicity Criteria [version 3.0]) observed in 33% of patients (47% in Group A and 9% in Group B; P = .05). The median time to onset of the TFR was 6 days, and was longer in the patients receiving prophylaxis (4 days vs 9 days, respectively; P = .01). A complete response was observed in 7 of 30 (23%) patients with TFR and 1 of 15 (7%) patients without TFR. The median progression-free survival was 19.9 months and 19.4 months, respectively, for patients with versus those without TFR (P = .92). CONCLUSIONS:TFR is a unique immune-mediated phenomenon noted with lenalidomide treatment only in patients with CLL that correlates with clinical response. It can be effectively managed with anti-inflammatory agents. 2010 American Cancer Society.
Authors: Bruce D Cheson; John C Byrd; Kanti R Rai; Neil E Kay; Susan M O'Brien; Ian W Flinn; Adrian Wiestner; Thomas J Kipps Journal: J Clin Oncol Date: 2012-07-09 Impact factor: 44.544
Authors: Xavier C Badoux; Michael J Keating; Sijin Wen; Bang-Ning Lee; Mariela Sivina; James Reuben; William G Wierda; Susan M O'Brien; Stefan Faderl; Steven M Kornblau; Jan A Burger; Alessandra Ferrajoli Journal: Blood Date: 2011-07-01 Impact factor: 22.113
Authors: Kami Maddocks; Lai Wei; Darlene Rozewski; Yao Jiang; Yuan Zhao; Mikhil Adusumilli; William E Pierceall; Camille Doykin; Michael H Cardone; Jeffrey A Jones; Joseph Flynn; Leslie A Andritsos; Michael R Grever; John C Byrd; Amy J Johnson; Mitch A Phelps; Kristie A Blum Journal: Am J Hematol Date: 2015-02-25 Impact factor: 10.047
Authors: Paolo Strati; Michael J Keating; William G Wierda; Xavier C Badoux; Steliana Calin; James M Reuben; Susan O'Brien; Steven M Kornblau; Hagop M Kantarjian; Hui Gao; Alessandra Ferrajoli Journal: Blood Date: 2013-06-25 Impact factor: 22.113
Authors: Han W Tun; Patrick B Johnston; Lisa M DeAngelis; Pamela J Atherton; Levi D Pederson; Patricia A Koenig; Craig B Reeder; Antonio M Padula Omuro; David Schiff; Brian O'Neill; Jose Pulido; Kurt A Jaeckle; Christian Grommes; Thomas E Witzig Journal: Blood Date: 2018-09-27 Impact factor: 22.113
Authors: Kami Maddocks; Amy S Ruppert; Rebekah Browning; Jeffrey Jones; Joseph Flynn; Cheryl Kefauver; Yue Gao; Yao Jiang; Darlene M Rozewski; Ming Poi; Mitch A Phelps; Erica Harper; Amy J Johnson; John C Byrd; Leslie A Andritsos Journal: Leuk Res Date: 2014-05-29 Impact factor: 3.156